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Abstract
Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were
analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis
of such cases. All samples coexpressed CK7 and CA9; the TFE3 or TFEB reactions were negative; the CD10 and the AMACR
stainings were negative in 27 cases and 30 cases, respectively. The FISH assays for papillary RCC, available in 27 cases, and
deletion of chromosome 3p, available in 29 cases, gave negative results. The results for 3p deletion, VHL gene mutation or VHL
gene promoter region hypermethylation testing, along with the diffuse CD10-positivity in 2 cases confirmed 21 cases as clear cell
papillary RCC (CCPRCC; CK7+, CA9+; no 3p loss, no VHL abnormality) and 10 cases as clear cell RCC (CCRCC; CK7+,
CA9+; no 3p loss, VHL abnormality mutation/hypermethylation present). In CCPRCCs, the representative growth pattern was
branching tubulo-acinar, commonly accompanied by cyst formation. The linear nuclear arrangement or cup-shaped staining of
CA9 did not necessarily indicate CCPRCC, and the absence of these did not exclude the diagnosis of CCPPRC. One tumor
infiltrated the renal sinus; the others exhibited pT1 stage; and metastatic outcome was not recorded. The CCRCC cases were in
pT1 stage; 6 exhibited cup-shaped staining of CA9, and 1 displayed lymph node metastasis at the time of surgery. Distant
metastatic disease was not observed. In summary, the VHL abnormalities distinguished the subset of CCRCC with diffuse CK7-
positivity and no 3p loss from cases of CCPRCC.
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Introduction
Clear cell papillary renal cell carcinoma (CCPRCC) is an in-
frequent subset of RCC [1, 2]. Although CCPRCC shares
histopathogical features with clear cell RCC (CCRCC), pap-
illary RCC and Xp11.2 translocation RCC, its immunohisto-
chemical coexpression of cytokeratin 7 (CK7) and carbonic
anhydrase 9 (CA9), and negativity for CD10, alpha-methyl-
CoA racemase (AMACR), and TFE3 usually clarifies the di-
agnosis [3–7]. The renal angiomyoadenomatous tumor (RAT)
is now regarded as being in the spectrum of CCPRCC [8–10].
Genetically, CCPRCCs lack chromosome 3p deletion or VHL
gene mutation or VHL promoter hypermethylation, the hall-
marks of CCRCC, and have no loss of chromosome Yor gain
of chromosome 7 and 17, the hallmarks of papillary RCC
[2–4, 11–13].
In surgical pathology practice, the separation of CCPRCCs
from CCRCCs can pose certain difficulties. The distinction is
crucial, because CCPRCCs have a very limited potential for
metastasis (fatal outcome has been reported only in two pa-
tients out of 400 [14]), whereas in low-grade CCRCCs distant
metastases can occur several years after nephrectomy. To learn
more about the differential diagnosis of low-grade RCCs with
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CCPRCC features, a series of such tumors were subjected to a
retrospective immunohistochemical analysis, applying CK7,
CA9, CD10, AMACR, TFEB and TFE3 immunostainings,
and the immunophenotypes were correlated with the results
of genetic markers for CCRCC or papillary RCC.
Materials and Methods
Case Selection and Review Process
This study was conducted with the permission of the Medical
Research Council (17489-4/2017/EKU). The hematoxylin
and eosin-stained slides of 2326 consecutive RCC samples
were reexamined for clear cell papillary RCC-like tumors,
including low-grade nuclei, the presence of any degree of
tubulopapillary growth pattern of tumor cells with clear cyto-
plasm, linear arrangement of nuclei away from the basal mem-
brane, along with the presence of a leiomyomatous stroma.
Demographical and clinical data were collected from the da-
tabase management systems of Semmelweis University and
University of Szeged.
Tissue Microarray and Immunohistochemical
Reactions
Tissue microarray blocks were prepared for immunohisto-
chemistry with TMA Master (3DHISTECH) applying a
2 mm core diameter. One to four representative cores were
t h e n p u n c h e d o u t f r o m t h e d o n o r b l o c k s .
Immunohistochemical staining for CA9, CK7, CD10,
AMACR, TFEB and TFE3 were performed (see the
dilutions and sources in Supplementary Table 1). The epitope
retrieval was performed for each antibody according to the
manufacturer’s recommendations. The reactions were con-
ducted using Autostainer (Dako). Afterwards, slides were
evaluated microscopically by estimating the proportion (%)
of immunopositive cells. Staining in over 50% of the tumor
cells, in 10 to 50% of tumor cells, or in less than 10% of the
tumor cells, was interpreted as diffusely or focally positive or
negative, respectively.
Fluorescent in Situ Hybridization (FISH)
FISH assays were carried out to detect either the loss of chro-
mosome 3p and chromosome Yor gain of chromosome 7 and
17. Tissue sections were cut from the TMA blocks and
deparaffinized. The assays were done using a VHL/cen3 probe
(ZytoLight® SPEC VHL/CEN3 Dual Color Probe,
Zytovision,) and centromeric probes for chromosome 7, 17
and Y (Cytocell) according to the manufacturer’s instructions.
Slides were digitalized by using a Pannoramic Midi slide
scanner (3DHISTECH), and reactions were evaluated using
a Pannoramic Viewer (3DHISTECH) in the following way.
Fifty tumor cells from each case were examined and were
compared with the same number of cells of the peritumoral
tissue, which served as an internal control. The cutoff values
of chromosomal gain and/or loss were set at the mean ±3SD of
the corresponding control values, as done in previous studies
[5]. The analysis of 3p deletion was also performed based on a
published method [15].
VHL Gene Sequence Analysis and VHL Gene Promoter
Hypermethylation
A PCR-based amplification method was used for VHL gene
mutation analysis as earlier described [16]. The VHL exons
were amplified via specific primer pairs (Supplementary
Table 2). In the case of pathological mutation, the apparently
tumor-free renal tissue was analyzed as well. A GenomeLAB
DTCS - Quick Start Kit (Beckman Coulter) was used for
DNA sequencing. The latter was carried out according to the
manufacturer’s instructions using the GenomeLab GeXP
Genetic Analysis System (Beckman Coulter). The methyla-
tion status of VHL gene promoter region was determined
using the methylation-specific PCR method. The extracted
genomic DNA was modified using the EpiJET Bisulfite
Conversion Kit (ThermoFischer Scientific), and followed by
PCR-based amplification with methylation-specific primer
pairs (Supplementary Table 3). The methylation status (non-
methylated, methylated) was determined by gel electrophore-
sis of the PCR products, as reported previously [17].
Criteria for Diagnosing a Tumor as CCPRCC
The diagnosis of CCPRCC was made if the above-mentioned
morphology together with characteristic immunophenotype
(CK7- and CA9-positivity, negative CD10 or at most focal
CD10-positivity, negative TFE3 and TFEB stainings), along
with the lack of genetic alterations indicating CCRCC (3p
deletion, VHL mutation, VHL promoter hypermethylation),
and PRCC (7 and 17 trisomy, loss of Y) were detected.
Tumors with the same morphology, CK7 and CA9
coexpression, but with diffuse CD10-positivity or with altered
VHL status were classed as CCRCC.
Results
Using the inclusion criteria, we retrieved 31 samples. All tu-
mors coexpressed CK7 and CA9. The TFE3 and TFEB reac-
tions were uniformly negative; and the CD10 and the
AMACR reactions were negative in 27 and 30 cases, respec-
tively. The FISH assays for papillary RCC, available in 27
cases, and deletion of chromosome 3p, available in 29 cases,
yielded negative results. The histomorphology, the results for
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VHL mutation and VHL methylation testing, and the
immunophenotype confirmed 21 cases as CCPRCC and 10
cases as CCRCC. The principal characteristics of the two sub-
sets are summarized in Tables 1 and 2.
Features of CCPRCCs
Here, 21 tumors were examined, and the specimens were ob-
tained from 12 females and 9 males. The mean age was 60
years (with range 28 to 84 years). Partial nephrectomy was
performed in 4 patients and radical nephrectomy in 17 pa-
tients; and one tumor developed in a transplanted kidney.
Twenty cases were incidental findings of imaging performed
for non-urological symptoms.
Gross Findings
All the tumors were solitary, and the mean size was 23 mm
(with range 6 to 65 mm). Cystic change was present in 12
samples; and multilocular cystic mass existed in cases 7 and
15. The tumorous parenchyma was grey-white to yellow-
brown, occasionally with small hemorrhagic foci.
Microscopic Findings
Each tumor was circumscribed, and at least one thin fibrous,
or fibromuscular capsule was present, except in one case. The
capsule was thick (400-800 μm) and contained smooth mus-
cle in 13 tumors. A minimal infiltration of renal sinus fat was
observed in Case 3 (Fig. 1a, b). Vascular invasion was not
detected in any of the cases examined. The dominant growth
pattern was tubulo-acinar (15 tumors), with cyst formation in a
continuum from microscopic to macroscopic cystic spaces in
12 samples. Also, a papillary architecture was observed in 14
tumors and was detected mainly focally, except in one case
where it was predominantly seen. Solid areas with compact
cell nests and trabeculae were seen in 11 samples, and it was
mostly made up of a small proportion of the tumorous paren-
chyma. Foamy macrophages, psammoma bodies and necrosis
were absent. Although the clear cell phenotype was a distinc-
tive feature, the tumor cells displayed various cytological
characteristics. Most of them were cuboidal or columnar, but
flattened forms in cysts, as well as elongated cells arranged
focally in a fascicular pattern in solid areas were also encoun-
tered. Some tumor cells – especially in solid areas – had eo-
sinophilic cytoplasm. Prominent nucleoli were not present.
The linear arrangement of nuclei together with its orientation
away from the basement membrane was observed in 16 tu-
mors (from a minimal to an extensive presence). Mitotic fig-
ures were occasionally seen. Stromal smooth muscle was
found in 18 cases including two samples with abundant myo-
matous stroma (cases 1 and 7).
Immunohistochemical and Molecular Profile
All tumors exhibited a strong and diffuse CK7 expression.
Immunoreaction for CA9 resulted in diffuse staining in 17
tumor samples, and focal staining in 4 tumor samples. The
Bcup-shaped^ pattern was detected in 17 cases, visible mainly
in the tubular and cystic areas. Focal CD10-positivity was
found in 2 samples. Weak granular, diffuse AMACR-
positivity was noted in Case 14.
The mutation status of the VHL gene was investigated in 11
samples, and in Case 12, single nucleotide polymorphism (SNP)
in untranslated region (UTR) was found. The VHL gene promot-
er hypermethylation statuswas analyzed in 16 samples; and none
of these harbored promoter region hypermethylation.
Follow-up
The median time was 52.5 months (with range 1 to 184
months). Three patients did not have a follow-up, and two
patients died in non-cancer-related causes. No evidence of
tumor progression and recurrence was documented in the data
of the 18 surviving patients.
Features of CCRCCs Mimicking CCPRCC
In this group, we analyzed 10 cases, and the mean age was 51
years (with range 37 to 69 years) with 5 female and 5 male
patients. Half of the cases were treated via partial nephrectomy.
Tumor-related symptomswere registered in two patients. In Case
23, a CCRCC (CA9 and CD10: diffusely positive; CK7 nega-
tive) was resected from the contralateral kidney twomonths after
the first surgery. And in Case 24, a metastatic perihilar lymph
nodewas removed together with the tumorous kidney (Fig. 1c-f).
Gross Findings
The mean size of the tumors was 29 mm (with range 15 to 50
mm). Cystic change was noticed almost in all cases (9/10).
The cut surface was indistinguishable from those seen in
CCPRCC.
Microscopic Findings
A capsule containing smooth muscle was present in 6 cases.
The predominant growth pattern was tubulo-acinar (5/10),
followed by cystic (2/10), papillary (1/10) and solid (1/10).
In Case 29, the distribution of tubulo-acinar, papillary and
cystic pattern was the same. The tumors were composed of
clear cytoplasm cells with focal eosinophilic granulations.
Also, an apical linear nuclear arrangement was noted in 6
cases, and 2 cases contained a smooth muscle rich stroma.
The infiltration of the renal vein, renal sinus and perinephric
fat tissue was not observed.
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Immunohistochemical and Molecular Profile
There was a coexpression of CK7 in a diffuse fashion
and CA9 in a diffuse (8 cases) or focal fashion (2
cases). The cup-shaped distribution of CA9 was present
in 6 cases. Diffuse CD10-positivity was observed in
cases 23 and 24.
The VHL gene mutation status was analyzed in 9 sam-
ples, and in cases 22, 23 and 31 a pathogenic mutation
was identified that was not present in the tumor-free
renal parenchyma (Fig. 2). The sequencing revealed an
SNP without any clinical significance in Case 24. The
remaining 5 tumors analyzed harbored no genetic
change. Also, the VHL gene promoter hypermethylation
was tested in 8 cases, and 7 of them possessed promoter
region hypermethylation.
Follow-up
All the cases had follow-up data with a median of 31.6months
(with range 3 to 100 months). None of them experienced any
recurrence and cancer-related death.
Table 1 Clinicopathological features of the cases examined
Patient Sex Age (y) ESRD Tumor-related
symptoms
Size (mm) AJCC Stage ISUP Grade Follow-up
period
(months)*
Progression§ Comment
Clear cell papillary RCC
1 M 68 No No 21 T1aNxMx 1 31 No
2 M 57 No No 20 T1aNxMx 2 35 No
3 M 64 No No 30 T3aNxMx 2 NA ND Sinus fat tissue infiltration
4 F 68 No No 30 T1aNxMx 1 12 No
5 M 84 ESRD No 10 T1aNxMx 1 1 No
6 F 63 No No 8 T1aNxMx 2 46 No Ipsilateral oncocytoma
7 F 81 No No 25 T1aNxMx 1 113 No
8 F 78 No No 20 T1aNxMx 1 184 No
9 M 56 ACKD No 10 T1aNxMx 1 85 No
10 M 66 No No 11 T1aNxMx 1 3 No
11 F 49 No No 38 T1aNxMx 1 10 No
12 M 75 No No 65 T1bNxMx 2 80 No
13 F 52 No No 25 T1aNxMx 2 158 No
14 M 32 No No 8 T1aNxMx 1 101 No
15 F 57 No No 6 T1aNxMx 1 NA ND
16 F 30 ESRD No 8 T1aNxMx 1 86 No
17 F 60 No Abdominal pain 22 T1aNxMx 1 3 No
18 M 76 No No 10 T1aN0Mx 1 62 No Ipsilateral angiomyolipoma
and papillary adenomas
19 F 69 No No 13 T1aNxMx 1 8 No
20 F 28 ESRD No 20 T1aNxMx 2 59 No Tumor in a graft kidney
21 F 56 No No 30 T1aNxMx 1 NA ND
Clear cell RCC
22 F 41 No No 20 T1aNxMx 1 26 No
23 F 44 No No 50 T1bN1Mx 1 36 No Lymph node metastasis
24 M 37 No Hematuria 37 T1aNxMx 1 67 No Contralateral clear cell RCC
two months later
25 M 47 ACKD No 19 T1aNxMx 1 12 No
26 F 53 No No 30 T1aNxMx 1 19 No
27 F 69 No No 24 T1aNxMx 2 37 No
28 M 69 No Lumbar pain 15 T1aNxMx 1 100 No Ipsilateral papillary adenoma
29 M 40 No No 30 T1aNxMx 1 10 No
30 F 51 No No 40 T1aNxMx 1 3 No
31 M 61 No No 25 T1aNxMx 2 6 No
*Follow-up, determined from the surgery to the last follow-up; §Progression, assessed by radiological and/or autopsy data
M male; F female; ESRD end-stage renal disease; ACKD acquired cystic kidney disease; NA not available; ND no data
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Discussion
The WHO classification of RCCs defines the subsets via a
synthesis of histopathological, immunohistochemical, and ge-
netic data [1]. In the current study, we focused on the discrim-
ination of CCPRCC from other tumor types by applying the
well-known immunohistochemical markers supplemented
with a molecular analysis that seeks to find chromosomal
abberations and VHL abnormalities (including mutations as
well as methylation analysis). We made a formal diagnosis
of CCPRCC when both the immunohistochemical and the
genetic tests were in complete accordance with the histology.
All the RCC subtypes with clear cell phenotype (i.e. TFE3
or TFEB translocation RCCs, TCEB1-mutated RCC [18],
Table 2 Morphological, immunohistochemical, and molecular characteristics of the cases examined.
Patient Architecture of tumor volume (%) Immune profile (%) Molecular characteristics
Tubular Papillary Cystic Solid LiN CK7 CA9 CA9 cup-shaped CD10 AMACR +7 +17 -
Y
-
3p
VHL mut VHL met
Clear cell papillary RCC
1 90 - - 10 No Diff Diff Yes Neg Neg - - - - wt ua
2 88 2 - 10 Yes Diff Diff Yes Foc Neg - - - - wt -
3 95 - - 5 Yes Diff Diff Yes Neg Neg nd nd nd nd nd nd
4 59 1 20 20 Yes Diff Diff Yes Neg Neg - - - wt -
5 100 - - - Yes Diff Diff Yes Neg Neg - nd - - nd nd
6 95 5 - - Yes Diff Diff Yes Foc Neg - - - wt -
7 44 5 50 1 No Diff Diff Yes Neg Neg - - - wt -
8 50 50 - - Yes Diff Diff Yes Neg Neg - - - ua -
9 80 10 - 10 No Diff Diff Yes Neg Neg - - - - wt -
10 95 5 - - Yes Diff Diff Yes Neg Neg - - - - wt -
11 50 40 10 - Yes Diff Diff Yes Neg Neg - - - wt -
12 50 - 50 - Yes Diff Diff Yes Neg Neg - - - - 5’UTR SNP# -
13 - 80 20 - No Diff Diff Yes Neg Neg - - - ua -
14 80 10 10 - Yes Diff Diff Yes Neg Poz§ - - - - wt -
15 - 20 80 - Yes Diff Diff No Neg Neg - - - ua nd
16 95 - - 5 Yes Diff Diff No Neg Neg - - ua nd
17 50 20 30 - No Diff Diff No Neg Neg - - - wt -
18 90 - 5 5 Yes Diff Foc Yes Neg Neg nd nd nd nd nd -
19 45 1 50 4 Yes Diff Foc Yes Neg Neg - - - nd -
20 89 - 1 10 Yes Diff Foc Yes Neg Neg - - - ua -
21 85 1 5 10 Yes Diff Foc No Neg Neg - - - ua -
Clear cell RCC
22 50 5 35 10 Yes Diff Diff Yes Neg Neg - - - muta +
23 50 20 30 - Yes Diff Diff Yes Diff Neg nd nd - mutb nd
24 10 50 20 20 No Diff Diff No Diff Neg - - - - 5’UTR SNP¶ -
25 80 10 10 - No Diff Diff Yes Neg Neg - - - - wt +
26 95 1 - 4 Yes Diff Diff Yes Neg Neg - - - wt +
27 20 10 70 - Yes Diff Diff Yes Neg Neg - - - wt +
28 40 - 60 - Yes Diff Diff Yes Neg Neg - - - - ua +
29 20 40 40 - Yes Diff Diff No Neg Neg - - - - wt +
30 30 - 20 50 No Diff Foc No Neg Neg - - - wt +
31 90 - - 10 Yes Diff Foc No Neg Neg - - - - mutc nd
LiN linear nuclear arrangement from basement membrane;+7 and +17 trisomy of chromosome 7 and 17, respectively; -Y deletion of chromosomeY; -3p
deletion of chromosome 3p; VHL mut, von Hippel-Lindau gene mutation status; VHL met, von Hippel-Lindau gene methylation status; nd not
determined; wt wild type; ua unsuccessful analysis; 5’UTR SNP single nucleotide polymorphism in 5’ untranslated region; diff diffuse; foc focal; neg
negative (less than or equal to 10%)
§ weak granular positivity; # exon 3 could not be amplified; ¶ exon1b could not be amplified; a c.221T>A/p.V74N; b c.625C>T/p.G209*; c c.354_
361delCTTCAGAGinsT
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RCC with 8p monosomy [19], RCC with prominent smooth
muscle stroma (RCCSMS) [20–25] and RCC associated with
von Hippel-Lindau syndrome) can exhibit a CCPRCC-like
histomorphology [26, 27], but CCRCC cases pose the biggest
difficulty because this tumor type is the most common and it
also has some morphological similarities. CCRCCs are
viewed as tumors that are CA9+ and CD10+, and display no
more than a focal CK7 positivity. In contrast, the
immunophenotype of CCPRCCs is CK7+, CA9+, and
CD10-. Perhaps diffuse and strong CK7 positivity is consid-
ered the most important and an obligatory diagnostic criterion
for CCPRCC. Nevertheless, the lack of a widespread CD10
reaction is also required.
We performed our case selection based on histological
features suggestive of CCPRCC, and all the tumors
displayed diffuse CK7 staining. In two of them, however,
Fig. 1 a-b Case 3 with sinus fat invasion The tumor showed a
branching tubular pattern and an immunophenotype characteristic for
CCPRCC (basolateral CA9 reaction in the insert) (a). Superficial
infiltration of sinus fat was seen (b). Figure 1 c-f Case 23 with lymph
node metastasis The tumor displayed the morphological features of
CCPRCC, partly with papillary architecture (c). The lymph node
metastasis was mainly cystic; with some papillary infoldings (insert in
figure d) (d). The tumor exhibited a diffuse CK7 positivity (e), but
extensive CD10 staining was also observed (f). The latter, together with
the VHL genemutation detected in this tumor were not consistent with the
diagnosis of CCPRCC
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CD10 positivity was also diffuse, which supported our
diagnosis of CCRCC. In another subset of our cases,
the morphology and immunophenotype wholly favoured
the diagnosis of CCPRCC; however, either VHL muta-
tion (3 cases) or VHL promoter hypermethylation (7
cases) was present. We accepted the view of Hes et al.
who recommended not classifying cases with any VHL
gene abnormality as CCPRCC [28]. Based on their ap-
proach, our tumors with altered VHL status were classi-
fied as CCRCC.
After performing an immunohistochemical and molecular
analysis, our selected cases with histology of CCPRCCs were
subdivided into two groups. These are CCPRCCs (21 cases),
and CCRCCs with diffuse CK7 positivity (10 cases).
Features of CCPRCC Cases
The characteristic pattern of these tumors was branching
tubulo-acinar that was commonly accompanied by cyst for-
mation. Papillary areas, however, were detected as a minor
Fig. 2 Case 22 exhibiting morphology and immunophenotype
completely consistent with CCPRCC, but containing a VHL gene
mutation. The tumor had a thick fibromyomatous capsule and it was
composed of both solid and cystic areas (a). Branching tubular
architectural pattern was the most characteristic (b). The tumor cells
were diffusely positive for CK7 (c); and negative for CD10 (d). CA9
immunoreaction also resulted in a diffuse staining with a basolateral
pattern (e). VHL gene mutation was detected by direct sequencing (f)
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component except in three cases. As similar findings on the
extent of papillarity were obtained by Aydin et al. [5] and by
Williamson et al. [29], we conclude that CCPRCC with pre-
dominant papillarity probably occurs quite rarely. Therefore,
the WHO designation of this entity seems inaccurate, and the
appellation Btubulopapillary^ would perhaps be more apt, as
was suggested by Aydin et al [5].
Linear nuclear arrangement away from the basement mem-
brane is regarded as characteristic for CCPRCC [30].
Actually, 16/21 of CCPRCCs and 7/10 CCRCCs with diffuse
CK7-positivity harbored this phenomenon (from a minimal to
extensive presence). Dhakal et al. examined 37 tumors with a
morphologic overlap between CCPRCC and CCRCC fea-
tures, and linear nuclear arrangement was not the exclusive
feature of cases classified as CCPRCC [31]. In another series
of CCPRCC, Williamson at al. noticed linear nuclear arrange-
ment only in 24/55 cases [32]. These findings suggest that
linear nuclear arrangement is an overemphasized phenome-
non, since its absence does not exclude the possible diagnosis
of CCPRCC, and its presence does not necessarily support the
diagnosis of CCPRCC.
The cup-shaped expression of CA9 was not uniformly
present in our series. A diffuse cup-shaped expression was
observed in 17/21 samples, while a dominant box-shaped
staining with a focal cup-shaped expression was noted in 4/
21 samples. Upon reviewing the literature, a cup-shaped ex-
pression involving 50% of tumor cells was reported by Rohan
et al. in 3 out of their 9 cases [6]; and Dhakal et al. noted a cup-
like expression of CA9 in 74% of their cases [31]; and Aydin
et al. did not mention this feature at all in their 36 cases [5].
Since in our experience the cup-shaped staining pattern cannot
be discerned unambiguously in solid areas, the absence of
cup-shaped expression should be interpreted with caution
when making a concrete diagnosis of CCPRCC for a specific
case. A diffuse and weak granular AMACR-positivity was
seen in one case. We reviewed the immunoprofile of the pub-
lished CCPRCC cases and, albeit rarely, AMACR-positivity
was reported [5, 6, 11, 29, 32–34]; hence if it is present, it does
not necessarily contradict the diagnosis of CCPRCC. Focal
CD10-positivity was encountered in two, otherwise complete-
ly typical CCPRCC, and VHL gene abnormalities were not
present in these samples. The focal extent of CD10 expression
may indicate the possibility of RAT, because a lack of a cystic
component viewed microscopically, and the triple
coexpression of CK7, CA9 and a certain degree of CD10 were
noted in a series of RCC cases classified as RAT [35].
Our CCPRCC group comprised 19 pT1a, 1 pT1b and 1
pT3a cases, respectively. To our knowledge, ours is the first
reported case with infiltration outside of the kidney parenchy-
ma. Also, in Case 20 the tumor developed in a transplanted
kidney. In a recently published review, Dhakal at al. [36] sum-
marized the findings of 24 articles that reported tumors in
transplanted kidneys, but among the 48 tumors described,
not one was CCPRCC. Coexisting benign tumors and
CCPRCC were observed in two cases. Actually, in Case 6
the oncocytoma had been detected clinically, and during
the grossing CCPRCC was discovered. All of our CCPRCC
cases had an excellent clinical outcome, reinforcing the
view that the carcinoma designation might be exaggerated
[14, 37, 38].
Features of CCRCCs with Diffuse CK7-Positivity
A series of CCRCC with diffuse CK7-posivity was published a
decade ago by Mai et al [39]. Similar to our experiences, these
samples were small-sized, and a non-metastatic course was re-
corded over a mean of a 3-year follow-up; and diffuse CK7-
positivity was viewed as the indicator of indolent behaviour [40].
Our results provide further clinicopathologic data on this
rare subset of CCRCC. Accordingly, neither 3p deletion, nor
other chromosomal anomalies were present. The VHL gene
sequence analysis revealed pathologic mutations in cases 22,
23 and 31. Since VHL mutations were not identified in the
non-tumorous renal tissue, the possibility of VHL-disease-
associated CCRCC was excluded.
In seven samples, the histological and immunphenotypic
data favoured the diagnosis of CCPRCC; however, the pres-
ence of the VHL gene promoter hypermethylation abnormality
leads us to place these samples into the CCRCC group. In the
study of Herman et al. on silecing of the VHL gene by DNA
methylation, the hypermethylation of a CpG island in the 5’
region was noted in 5 samples out of 26 CCRCCs [16]. Four
of these had lost one copy of VHL, while one retained two
heavily methylated alleles. The latter observation indicated
Table 3 Overlapping and discriminating features of CCRCCs and
CCPRCCs. As we accepted the view of Hes et al. [18] that VHL gene
alteration is not compatible with the diagnosis of CCPRCC, altered VHL
status was found as the most reliable discriminating feature between
CCRCCs and CCPRCCs in our cohort
Tubulopapillary
architecture
Subnuclear
vacuolization
Stromal
SM
Diffuse
CK7+
Diffuse
CD10+
CA9 cup-
shaped
-
3p
VHL
mut
VHL
met
CCCRCC +/- +/- +/- +/- +/- +/- +/- +/- +/-
CCCPRCC + +/- +/- + - +/- - - -
SM smooth muscle; mut mutation; met hypermethylaiton
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that hypermethylation may inactivate the VHL gene even
when both wild-type alleles are retained [16]. In our analysis,
hypermethylation was noted in seven cases; moreover
coexisting VHL gene mutation and methylation was seen in
Case 22. After a search for methylation data, only 2 tumors
analyzed were found in the literature out of 400 or so
CCPRCCs [5, 14]. Methylation analyses performed by others
in the futuremay validate our assumption that a VHL promoter
hypermethylation is definitely not compatible with the diag-
nosis of CCPRCC. In Case 24 (and in Case 12 in the
CCPRCC group) an SNP was observed in the 5’ UTR region,
a finding treated as insignificant, because the nucleotide
change did not induce any amino acid change as well.
Interestingly, in 8 cases the histological and immunphenotypic
data were entirely consistent with the histopathological diag-
nosis of CCPRCC, but the presence of VHL abnormalities led
us to place these samples into the group of low-grade CCRCC
with CK7 immunoreactivity and no 3p loss. Every case was in
the pT1 stage, and there was no progression or recurrence.
In summary, in our study the immunophenotype and the
genetic profile of 31 RCCs composed of clear cells, low-grade
nuclei and a tubulopapillary architecture were investigated
retrospectively. Twenty-one cases were classified as
CCPRCC (CK7+, CA9+; -3p absent, VHL abnormality not
present) and 10 as CCRCC with diffuse CK7-positivity
(CK7+, CA9+; -3p absent, VHL abnormality present). Based
on our findings, the following conclusions can be drawn. First,
CCPRCCs rarely exhibit a predominant papillary architecture,
hence their name is misleading. Second, a linear nuclear ar-
rangement away from the basement membrane and cup-like
CA9 positivity are not obligatory features. Third, the evidence
for their malignant potential is still subject of debate. Fourth,
RCCs with CCPRCC morphology, diffuse CK7 positivtiy,
and with an altered VHL status (mutation, or promoter hyper-
methylation) do exist; and these tumors can be interpreted as
CCRCCwith diffuse CK7 positivity, and they can be definite-
ly differentiated from CCPRCCs only by carrying out molec-
ular tests for the VHL status. And last but, not least the bio-
logical behavior of both CCPRCCs and CCRCCs with diffuse
CK7 positivity seems to be indolent with a favorable clinical
outcome. Overlapping and discriminating features of
CCPRCCs and CCRCCs are summarized in Table 3.
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